ALVEOLAR SURFACTANT PROTEIN

• Main Authors: BENSON BRADLEY J, SCHILLING JR JAMES W, BUCKLEY DOUGLAS I, SCARBOROUGH ROBERT M, WHITE ROBERT T
• Format: Patent
• Language: English
• Published: 03.03.2005
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide specific human SP-18 and SP-5 derived proteins relating to alveolar surfactant proteins (ASP) in general useful for treating specific respiratory diseases. SOLUTION: The proteins are purified polypeptides having an ASP activity and a sequence shown below, or its pharmaceutically permissible salt or amide: X-AA28-AA29-AA30-AA31-AA32-AA33-AA34-AA35-Leu-Leu-Ile-Z-Z-Z-Z-Z-Z-Leu-Ile-Z-Z-Z-Ile-Z-Gly-Ala-Leu-Leu-Met-Y. Some of these proteins, being analogs of encoded sequences, exhibit remarkably decreased aggregation in comparison with natural proteins, i.e., the aggregation caused by intramolecular and intermolecular interactions, mainly due to disulfides of covalent bonds, decreases. The SP-5 derived peptide maintains not only the biological activity of natural polypeptides but also chemical and physical stabilities. COPYRIGHT: (C)2005,JPO&NCIPI